Sheets Smith Wealth Management Neurocrine Biosciences Inc Transaction History

Sheets Smith Wealth Management

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 30, 2024	BUY	$130.86 - $143.19 $13,216 - $14,462	101 Added 4.91%	2,159 $297,000
Q1 2024 May 08, 2024	BUY	$130.4 - $143.74 $1,173 - $1,293	9 Added 0.44%	2,058 $283,000
Q4 2023 Feb 06, 2024	BUY	$106.07 - $132.76 $217,337 - $272,025	2,049 New	2,049 $269,000
Q1 2020 Apr 28, 2020	SELL	$75.11 - $113.76 $377,653 - $571,985	-5,028 Closed	0 $0
Q4 2019 Jan 24, 2020	BUY	$86.8 - $118.57 $436,430 - $596,169	5,028 New	5,028 $536,000

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Sheets Smith Wealth Management, based on Form 13F filings with the SEC.

Stay updated on Sheets Smith Wealth Management with notifications on news.